Journal of Postgraduate Medicine
 Open access journal indexed with Index Medicus & ISI's SCI  
Users online: 2191  
Home | Subscribe | Feedback | Login 
About Latest Articles Back-Issues Article Submission Resources Sections Etcetera Contact
 
  NAVIGATE Here 
  Search
 
 :: Next article
 :: Previous article 
 :: Table of Contents
  
 RESOURCE Links
 ::  Similar in PUBMED
 ::  Search Pubmed for
 ::  Search in Google Scholar for
 ::  Article in PDF (113 KB)
 ::  Citation Manager
 ::  Access Statistics
 ::  Reader Comments
 ::  Email Alert *
 ::  Add to My List *
* Registration required (free) 

  IN THIS Article
 ::  References

 Article Access Statistics
    Viewed7045    
    Printed196    
    Emailed11    
    PDF Downloaded247    
    Comments [Add]    
    Cited by others 5    

Recommend this journal


 


 
EDITORIAL
Year : 2006  |  Volume : 52  |  Issue : 3  |  Page : 161-162

HIV, research, ethics and women


1 Department of Obstetrics and Gynecology, Seth GS Medical College and King Edward Memorial Hospital, Parel, Mumbai, India
2 Department of Obstetrics and Gynecology, Seth GS Medical College, Nowrosjee Wadia Maternity Hospital, Mumbai, India

Correspondence Address:
Vinita Salvi
Department of Obstetrics and Gynecology, Seth GS Medical College and KEM Hospital, Parel, Mumbai
India
Login to access the Email id

Source of Support: None, Conflict of Interest: None


PMID: 16855313

Rights and PermissionsRights and Permissions




How to cite this article:
Salvi V, Damania K. HIV, research, ethics and women. J Postgrad Med 2006;52:161-2

How to cite this URL:
Salvi V, Damania K. HIV, research, ethics and women. J Postgrad Med [serial online] 2006 [cited 2020 Sep 20];52:161-2. Available from: http://www.jpgmonline.com/text.asp?2006/52/3/161/26533


HIV and AIDS offer tremendous opportunities for research given the need for discovering new strategies and agents for preventing and treating disease. The urge for developing new drugs and vaccines and the financial stakes involved pose ethical challenges to research workers in the field. Nowhere is this more relevant than in developing countries and more so in disadvantaged groups such as women and children. The ones who are most in the need of protection and those who need to be given access to the benefits of new developments are also the ones who are most likely to be exploited.

In several countries, HIV infection and AIDS are more commonly encountered amongst vulnerable populations; individuals who are poor, uneducated and hence powerless. They have a limited understanding of the disease, and a much more limited insight into their problems. Although newly infected individuals are not at risk of death in the near future, they are often pressured into entering clinical trials. They are approached at a time when they are in emotional shock[1] and hence very vulnerable. It is questionable if informed consent is properly implemented and if the prospective subjects understand the concept, its process of administration and its implications. Sastry et al[2] evaluated the overall understanding of key issues regarding informed consent about HIV/AIDS amongst pregnant women in the state of Maharashtra, in India. They estimated that, after group education and counseling (GEC), only 38% of women had understood six out of eight key issues. It has been suggested that ethics boards should be more innovative and explore the suitability, feasibility and effectiveness of new methods of conveying information (perhaps through videotapes or obligatory information sessions with independent counselors) to enhance understanding amongst prospective research subjects for HIV-related research studies.[1] This concept is appealing and should perhaps be utilized for all major trials and especially those that are industry sponsored and more so in developing countries. Sastry et al[2] have determined that 72% of women understood key issues when visual aids were used during group counseling sessions. Moreover, when these same visuals were used during individual counseling sessions, 96% of women comprehended key issues pertaining to informed consent.

There has been much debate and discussion in the scientific community about ensuring justice for trial participants. It is necessary that potential volunteers are adequately informed of both the long-and short-term consequences of initiating prolonged regimes of multiple anti-retroviral drugs. Ethically it is necessary to ensure that these participants have sustainability of care and access to drugs, even after the trial ends. Different groups have come up with innovative approaches to ensure that research participants continue to be provided with care through co-payments, pharmaceutical donations and drug funds.[3] However, the very concept of providing sustained care has, paradoxically, led to another ethical dilemma: Would the decision to participate in the trial or not be influenced by the prospect of receiving care and effective drugs? Wouldn't this act as an undue inducement? The likelihood of these considerations influencing the prospective volunteer is much more in resource-poor settings, since these projects often offer better quality care than that available through the public health sector.[3]

Various corporate or political groups may attempt to influence and control the study design; this is another matter for concern.[3] Researchers might subordinate subjects' welfare to the objectives of the study especially when the research question is extremely important and in their perception could provide an answer that would substantially improve the care in future.[4] This is especially true of trials pertaining to HIV and anti-retrovirals. Even well-meaning researchers may treat human subjects as a means to an end with their welfare being considered secondary to the ultimate research goal.

Placebo-controlled trials produce much faster results and are favored by the scientific community but in a situation such as HIV/AIDS, where accepted modes of intervention are available, it is unethical to conduct placebo-controlled trials. The AIDS clinical trials group (ACTG) Study 076 was the first randomized, controlled trial in which administration of the anti-retroviral drug zidovudine to HIV-positive pregnant women was proved to reduce the incidence of maternal-infant transmission of HIV infection.[5] Undoubtedly, there are many other anti-retrovirals as well as other methods for reduction of perinatal HIV transmission. These would necessarily have to be evaluated in randomized, double blind controlled studies. However, it is necessary that the control group receives an accepted mode of intervention such as zidovudine or nevirapine and not a placebo. In fact, these modalities should be made available to all the volunteers. It is unethical to have volunteers receiving placebo when a drug regimen, which has been proven to reduce transmission significantly is available. However, even after the ACTG study was completed, Lurie and Wolfe[6] identified 18 randomized, controlled trials of interventions to prevent perinatal HIV transmission with ethical guidelines being violated in 15 trials. The studies were designed to evaluate a variety of interventions, such as the use of anti-retrovirals, Vitamin A and vaginal washing in a total of over 17,000 women.

In the two studies being performed in the United States, the patients in all the study groups had unrestricted access to zidovudine or other antiretroviral drugs. In 15 of the 16 trials in developing countries, however, some (and at times none) of the patients were provided with antiretroviral drugs. Nine of these 15 studies being conducted outside the United States were funded by the US government through the CDC or the National Institutes of Health (NIH), 5 were funded by other governments and 1 was funded by the United Nations AIDS Program. The studies were being conducted in C τte d'Ivoire, Uganda, Tanzania, South Africa, Malawi, Thailand, Ethiopia, Burkina Faso, Zimbabwe, Kenya and the Dominican Republic. These 15 studies clearly violated ethical standards, which should have been as exacting as in the case of research carried out in the sponsoring country.

Trials that emanate from developed countries and that are conducted either partially or completely in developing countries are more susceptible to ethical violations. As Lurie and Wolfe correctly point out, acceptance of a standard of care that does not conform to the standard in the sponsoring country results in a double standard in research. These double standards, which permit research designs and practices that would be unacceptable in the sponsoring country, create an incentive to use under-privileged populations with least access to healthcare in resource-poor countries as research subjects.

Government bodies responsible for matters of public health and research have a huge responsibility. They must ensure that prospective subjects are offered appropriate and adequate information to base their decision on and are provided with optimum care during and after the trial in an ethically conducted research study.

The organizations indulging in research should be prompt in giving wider publicity to the research findings. For example, the National AIDS Control Organization (NACO), which is the nodal body for work on HIV/AIDS in India, has been successful in demonstrating the feasibility of short-term zidovudine prophylaxis for prevention of vertical transmission of HIV infection from the infected mother to her baby in a study conducted in India from April 2000 to July 2001 and the results are available at the NACO website.[7]

The HIVNET012 trial demonstrated the use of nevirapine prophylaxis in HIV positive pregnant women.[8] Subsequently, NACO incorporated the distribution of Nevirapine to HIV positive women in labor as a part of the Prevention of Parent to child transmission (PPTCT) Program in India. From January 2003 to June 2004, 4771 mother-baby pairs have received Nevirapine prophylaxis.[9] NACO should publish the results of the study so that the benefits and limitations of the interventions can be gauged by the scientific community and other resource poor communities can learn from these results.

The prophylactic use of anti-retrovirals in pregnancy for protecting the neonate has raised a number of ethical issues. Continuing research has led to the availability of new, more potent antiretroviral regimens to prevent vertical transmission of HIV infection to the fetus and baby. Further, new evidence is available regarding the safety of use of highly active antiretroviral therapy (HAART) in pregnant women. It is also known that administration of a single-dose of nevirapine could result in the development of resistant HIV strains. This could limit treatment options available to these women in future. A 7-day tail of AZT plus 3TC (Lamivudine) is used to reduce the risk of NVP resistance and the same has been incorporated in the WHO guidelines.[10],[11] However, WHO continues to include single dose nevirapine without the AZT plus 3TC tail as one of the alternative regimens for preventing parent to child transmission of HIV.[10],[11] In view of the potential for resistance is it appropriate for WHO to continue with this regimen in its guidelines?

With increasing globalization, the number of trials pertaining to HIV, in developing countries will only increase. A large proportion of these trials will be funded either by developed nations or the industry. The issue of protection of disadvantaged groups will be a major concern and it is necessary to ensure that the rights of research subjects are not trampled upon and that the research is conducted in conformity with the highest ethical standards.

 
 :: References Top

1.Silversides A. New ethical obligations accompany new HIV drugs, conference told. CMAJ 1999;161:187.  Back to cited text no. 1  [PUBMED]  [FULLTEXT]
2.Sastry J, Pisal H, Sutar S, Kapadia-Kundu N, Joshi A, Suryavanshi N, et al . Optimizing the HIV/AIDS informed consent process in India. BMC Med 2004;2:28  Back to cited text no. 2    
3.Principles and practices: The implementation of ethical guidelines for research on HIVhttp://www.who.int/hiv/strategic/mt020603/en/. Accessed on 14 July 2006.  Back to cited text no. 3    
4.Angell M. The ethics of clinical research in the Third World. N Engl J Med 1997;337:847-9.  Back to cited text no. 4  [PUBMED]  [FULLTEXT]
5.Connor EM, Sperling RS, Gelber R, Kiselev P, Scott G, O'Sullivan MJ, et al . Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994;331:1173-80.  Back to cited text no. 5    
6.Lurie P, Wolfe SM. Unethical trials of interventions to reduce perinatal transmission of the human immunodeficiency virus in developing countries. N Engl J Med 1997;337:853-6.  Back to cited text no. 6  [PUBMED]  [FULLTEXT]
7.Feasibility Study of Administering Short-Term Azt Intervention Among HIV-Infected Mothers To Prevent Mother-To-Child Transmission Of HIV In India http://www.nacoonline.org/prog_sche_prevent.htm Accessed on 11 July 2006  Back to cited text no. 7    
8.Guay LA, Musoke P, Fleming T, Bagenda D, Allen M, Nakabiito C, et al . Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomised trial. Lancet 1999;354:795-802.  Back to cited text no. 8    
9.Preventing Parent to Child Transmission http://www.nacoonline.org/directory_ptct.htm Accessed on 10 July 2006.  Back to cited text no. 9    
10.Antiretroviral drugs and the prevention of mother-to-child transmission of HIV infection in resource-limited settings. Recommendations for a Public Health Approach (2005Revision) http://www.who.int/3by5/PMTCTreport_June2005.pdf Accessed on 10 July 2006.  Back to cited text no. 10    
11.What's new in the PMTCT guidelines? http://www.who.int/hiv/mediacentre/fs_2006guidelines_pmtct/en/index.html Accessed on 10 July 2006.  Back to cited text no. 11    



This article has been cited by
1 How informed is consent in vulnerable populations? Experience using a continuous consent process during the MDP301 vaginal microbicide trial in Mwanza, Tanzania
Vallely, A., Lees, S., Shagi, C., Kasindi, S., Soteli, S., Kavit, N., Vallely, L., (...), Hayes, R.J.
BMC Medical Ethics. 2010; 11(1): art-10
[Pubmed]
2 Are women who work in bars, guesthouses and similar facilities a suitable study population for vaginal microbicide trials in Africa?
Vallely, A., Hambleton, I.R., Kasindi, S., Knight, L., Francis, S.C., Chirwa, T., Everett, D., (...), Hayes, R.J.
PLoS ONE. 2010; 5(5): art-10661
[Pubmed]
3 Microbicides Development Programme: Engaging the community in the standard of care debate in a vaginal microbicide trial in Mwanza, Tanzania
Vallely, A., Shagi, C., Lees, S., Shapiro, K., Masanja, J., Nikolau, L., Kazimoto, J., Hayes, R.J.
BMC Medical Ethics. 2009; 10(1): art no 17
[Pubmed]
4 Ethical and practical challenges in implementing informed consent in HIV/AIDS clinical trials in developing or resource-limited countries
Mystakidou, K., Panagiotou, I., Katsaragakis, S., Tsilika, E., Parpa, E.
Sahara J. 2009; 6(2): 46-57
[Pubmed]
5 Prevention of mother to child transmission of HIV infection
Damania Kaizad R, Tank Parikshit D
J Obstet Gynecol India. 2006; 56(5): 390-395
[Pubmed]



 

Top
Print this article  Email this article
Previous article Next article
Online since 12th February '04
2004 - Journal of Postgraduate Medicine
Official Publication of the Staff Society of the Seth GS Medical College and KEM Hospital, Mumbai, India
Published by Wolters Kluwer - Medknow